JPM vs. VRNA

Last updated Jun 24, 2026

JPM (JPMorgan Chase & Co.) and VRNA (Verona Pharma plc) are both stocks. JPM operates in Banks - Diversified (Financial Services), while VRNA operates in Biotechnology (Healthcare). At a 0.11 correlation, their price movements are largely independent.

Performance

JPM vs. VRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in JPMorgan Chase & Co. (JPM) and Verona Pharma plc (VRNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

JPM

• 1D: 0.80%
• 1M: 9.06%
• YTD: 4.70%
• 6M: 3.51%
• 1Y: 22.41%
• 3Y*: 37.10%
• 5Y*: 19.98%
• 10Y*: 22.02%

VRNA

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

JPM vs. VRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
JPM JPMorgan Chase & Co.	4.70%	37.27%	44.29%	30.63%	-12.64%	27.75%	-5.53%	47.26%	-6.62%	22.31%
VRNA Verona Pharma plc	0.00%	130.21%	133.60%	-23.92%	288.84%	-4.00%	21.74%	-40.41%	-18.71%	-12.07%

Correlation

The correlation between JPM and VRNA is 0.06, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.06
Correlation (3Y) Calculated over the trailing 3-year period	0.17
Correlation (5Y) Calculated over the trailing 5-year period	0.17
Correlation (All Time) Calculated using the full available price history since Apr 27, 2017	0.11

The correlation between JPM and VRNA shifts across timeframes, from 0.06 (1 year) to 0.17 (3 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap JPM : $933.49B VRNA : $9.72B
EPS JPM : $21.08 VRNA : -$0.69
PS Ratio JPM : 3.27 VRNA : 57.97
PB Ratio JPM : 2.71 VRNA : 34.92
Total Revenue (TTM) JPM : $285.09B VRNA : $167.65M
Gross Profit (TTM) JPM : $173.52B VRNA : $159.52M
EBITDA (TTM) JPM : $81.46B VRNA : -$40.86M

Return for Risk

JPM vs. VRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

JPM

JPM Risk / Return Rank: 68
JPM Sharpe Ratio Rank: 73
JPM Sortino Ratio Rank: 65
JPM Omega Ratio Rank: 65
JPM Calmar Ratio Rank: 69
JPM Martin Ratio Rank: 70

VRNA

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

JPM vs. VRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for JPMorgan Chase & Co. (JPM) and Verona Pharma plc (VRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	JPM	VRNA	Difference
Sharpe ratio: Return per unit of total volatility	1.02	—	—
Sortino ratio: Return per unit of downside risk	1.45	—	—
Omega ratio: Gain probability vs. loss probability	1.19	—	—
Calmar ratio: Return relative to maximum drawdown	1.46	—	—
Martin ratio: Return relative to average drawdown	3.43	—	—

Drawdowns

Drawdown Indicators

	JPM	VRNA	Difference
Max Drawdown Largest peak-to-trough decline	-76.16%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-15.47%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-24.42%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-38.77%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-43.63%	—	—
Current Drawdown Current decline from peak	0.00%	—	—
Average Drawdown Average peak-to-trough decline	-17.61%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	6.55%	—	—

Volatility

Volatility by Period

	JPM	VRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.34%	—	—
Volatility (6M) Calculated over the trailing 6-month period	17.14%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	22.12%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	24.47%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	27.35%	—	—

Dividends

JPM vs. VRNA - Dividend Comparison

JPM's dividend yield for the trailing twelve months is around 1.77%, while VRNA has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
JPM JPMorgan Chase & Co.	1.77%	1.72%	1.92%	2.38%	2.98%	2.34%	2.83%	2.37%	2.54%	1.91%	2.13%	2.54%
VRNA Verona Pharma plc	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

JPM vs. VRNA - Profitability Comparison

The chart below illustrates the profitability comparison between JPMorgan Chase & Co. and Verona Pharma plc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

JPM - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, JPMorgan Chase & Co. reported a gross profit of 47.33B and revenue of 73.66B. Therefore, the gross margin over that period was 64.3%.

VRNA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.

JPM - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, JPMorgan Chase & Co. reported an operating income of 20.48B and revenue of 73.66B, resulting in an operating margin of 27.8%.

VRNA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.

JPM - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, JPMorgan Chase & Co. reported a net income of 16.49B and revenue of 73.66B, resulting in a net margin of 22.4%.

VRNA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.

Frequently Asked Questions

Can I hold both JPM and VRNA in my portfolio?

JPM and VRNA have a correlation of 0.06, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.